QIAGEN Reports Strong Q1 2025 Results and Revises EPS Outlook

QIAGEN N.V. has released strong preliminary results for Q1 2025, surpassing expectations for net sales and adjusted earnings per share (EPS). The company has also updated its adjusted EPS outlook for the full year. QIAGEN reports an approximate 5% growth in net sales, reaching around $483 million, and exceeding the anticipated 3% growth at constant exchange rates (CER).

Sales of the QuantiFERON test for latent TB increased by 15% CER, benefiting from a global shift to modern blood-based tests. The QIAstat-Dx testing system grew over 35% CER, due to high demand for respiratory panels and growth in gastrointestinal and meningitis testing. QIAcuity digital PCR and QIAGEN Digital Insights bioinformatics reported solid gains, while sales in PCR consumables also contributed positively.

QIAGEN has raised its full-year 2025 adjusted diluted EPS outlook to about $2.35 CER from $2.28 CER, despite potential headwinds from U.S. tariffs and a favorable tax environment. The company remains committed to improving its adjusted operating income margin above 30% for the year.